Welcome to our dedicated page for Cumberland Pharmaceuticals news (Ticker: CPIX), a resource for investors and traders seeking the latest updates and insights on Cumberland Pharmaceuticals stock.
Cumberland Pharmaceuticals Inc. develops, acquires and commercializes branded prescription pharmaceutical products for hospital acute care, gastroenterology and oncology markets. Company news commonly covers operating results, product-portfolio updates and regulatory developments for FDA-approved brands such as Caldolor, Sancuso and Vaprisol.
Recurring updates also address Caldolor indication activity, Sancuso educational and commercial resources, and clinical or regulatory disclosures tied to Cumberland's ifetroban programs in systemic sclerosis, Duchenne muscular dystrophy-associated cardiomyopathy and idiopathic pulmonary fibrosis. Capital-structure items, material agreements and shareholder voting matters appear alongside the company's financial and portfolio updates.
RedHill (Nasdaq: RDHL) presented independent preclinical data at AACR 2026 showing that opaganib may enhance chemotherapy efficacy in high‑risk neuroblastoma and augment STING‑mediated anti‑tumor immunity in triple‑negative breast cancer (TNBC).
Penn State and Apogee data indicate opaganib destabilized n‑Myc and increased ceramide‑driven apoptosis with OXDOX; University of Kansas data show opaganib plus low‑dose diABZI potentiated STING effects in TNBC. Opaganib holds FDA Orphan and Rare Pediatric Disease designations for neuroblastoma.
Cumberland Pharmaceuticals (Nasdaq: CPIX) announced FDA approval on April 16, 2026 for an expanded indication of Caldolor (ibuprofen) Injection to include management of postoperative pain in adults and pediatric patients ages 3 months and older.
The company also launched a redesigned website for healthcare professionals featuring perioperative resources, dosing, safety, and J-Code reimbursement support.
Cumberland Pharmaceuticals (Nasdaq: CPIX) launched an updated Sancuso website on March 17, 2026, offering educational resources for chemotherapy-induced nausea and vomiting (CINV).
The site highlights Sancuso as the only prescription granisetron transdermal patch approved by the FDA to prevent CINV for up to five days, and includes clinical data, HCP tools, patient education, and prescribing information.
H. pylori infections market (CPIX) is projected to expand from a USD 270 million market in 2025 at a 9.4% CAGR through 2036 across the 6MM. US holds ~85% of 2025 revenue and ~57 million diagnosed prevalent cases; emerging therapies such as rifasutenizol, linaprazan glurate, and tegoprazan are expected to reshape treatment paradigms with reported Phase III eradication rates >90% for some candidates.
Challenges include a limited pipeline, geographic regulatory gaps, rising antibiotic resistance, and adherence issues with high pill burdens.
Cumberland Pharmaceuticals (Nasdaq: CPIX) reported Q4 2025 combined net revenues of $13.7M, up 31% year-over-year, and full-year 2025 net revenues of $44.5M, up 18% versus 2024. The company posted a $2.9M net loss for 2025 and $1.7M adjusted earnings. Total assets were $76.8M and shareholders' equity was $24.9M at year end.
Key developments: international launches/approvals, Talicia co-commercialization, permanent J-code for Caldolor, positive FIGHT DMD Phase II topline results and FDA fast track designation in early 2026.
Cumberland Pharmaceuticals (Nasdaq: CPIX) launched a national U.S. sales promotion for Talicia on Feb 25, 2026, under a co-commercialization agreement with RedHill Biopharma.
Talicia is an FDA-approved, all-in-one oral capsule for H. pylori, patent protected through 2042 with eight years of U.S. market exclusivity under QIDP; Cumberland will use its field sales force to expand prescriptions and patient access.
RedHill (Nasdaq:RDHL) and Cumberland (Nasdaq:CPIX) have begun the full U.S. sales and operational launch of Talicia under Talicia Holdings Inc. (THI), a 70/30 RedHill/Cumberland joint operating entity. Cumberland made a $4 million strategic investment and the joint model launched after an October 2025 agreement.
Talicia is positioned as the #1 branded U.S. gastroenterologist-prescribed H. pylori therapy, is patent-protected through 2042, holds eight years of U.S. market exclusivity (QIDP), and targets an estimated 1.6 million U.S. patients treated annually.
Cumberland Pharmaceuticals (Nasdaq: CPIX) will report its 2025 annual financial results and provide a company update after market close on March 3, 2026. A conference call is scheduled for March 3 at 4:30 p.m. ET with a replay available for one year.
The company highlighted its FDA-approved hospital, gastroenterology and oncology portfolio and noted ongoing Phase II trials for ifetroban in systemic sclerosis, DMD cardiomyopathy and idiopathic pulmonary fibrosis.
Cumberland Pharmaceuticals (Nasdaq: CPIX) announced that the FDA granted Fast Track Designation for oral ifetroban to treat Duchenne muscular dystrophy (DMD) heart disease on Feb 4, 2026. This follows prior Orphan Drug and Rare Pediatric Disease designations and builds on Phase 2 FIGHT DMD results showing a 5.4% LVEF improvement over 12 months.
The Fast Track status enables more frequent FDA interactions and rolling submission options to potentially accelerate review for this urgent, unmet pediatric cardiac indication.
Cumberland Pharmaceuticals (Nasdaq: CPIX) announced on Dec 8, 2025 that Caldolor® (ibuprofen) Injection's permanent J-code J1741 is now officially associated with a reimbursement price, creating a CMS-covered, non-opioid option for pain and fever management.
The update links an established reimbursement price to J1741, which the company says supports opioid-sparing strategies, encourages providers to update billing systems, and may improve access to Caldolor for adult and pediatric patients where ibuprofen is indicated.